MAP2K7 and melanoma: Although there may be issues with the treatment regimen used in our long-latency orthotopic xenografts, and the patient received trametinib only postprogression after several months on everolimus and radiation, there are also concerns over the emergence of resistance to MEK inhibition as previously described in melanoma or colorectal cancers (37–40).